drugset / Trial / NCT06529406
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A multi-center pilot study to evaluate safety and efficacy of ozanimod as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
Timeline
- Start
- 2024-07-29
- Primary completion
- 2028-08-01
- Completion
- 2029-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ozanimod | Small molecule | — | — |